Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.30 +0.17%

+$0.02 today

Market cap
$546.27M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.87M

Average 0.88M

CLYM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Climb Bio, Inc.NASDAQ: CLYM

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 68.21M shares rose 1.1% year over year, behind the +18.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +37.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.1% toward the trailing-twelve-month pace of +18.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
68.21M+1.2% QoQ
Last fiscal yearDec 2025
67.81M+40.8% YoY
LTMMar 2026
67.75M+18.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.1%——
1 year+40.8%——
3-year CAGR+37.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
67.81M USD
Year-over-year change
+40.8%
4-year CAGR
+53.4%

Weighted Avg Shares vs competitors

How CLYM compares with its peers on the latest reported figures

  • CLYM's LTM Mar 2026 weighted avg shares of 67.75M shares is the 3rd highest of the 5 companies compared; the peer median is 69.8M shares.
  • Its year-over-year change of +18.0% is the 3rd highest of 4, against a peer median of +48.0%.
  • Over three fiscal years its annual growth of +37.1% compares with a peer median of +51.6%.
CLYM Competitors Peer median
Weighted Avg Shares for CLYM and competitors
Company Period LTM YoY 3-year CAGR
CABACabaletta Bio, Inc.LTM Mar 202694.61M +91.6%+51.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +48.0%+78.9%
CLYMClimb Bio, Inc.LTM Mar 202667.75M +18.0%+37.1%
UPBUpstream Bio, Inc.LTM Mar 202654.07M +4.2%+14.0%
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
Peer median (excluding CLYM) 69.8M+48.0%+51.6%

Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000097K
Gross Profit0000(97K)
Gross Margin—————
Research & Development23.32M26.21M15.41M14.34M46.62M
Selling, General & Admin12.35M18.92M24.86M16.03M21.17M
Operating Expenses35.67M45.14M40.28M82.02M67.79M
Depreciation & Amortization000097K
EBITDA(47.48M)(45.24M)(35.12M)(30.36M)(59.75M)
EBITDA Margin—————
Operating Income(35.67M)(45.14M)(40.28M)(82.02M)(67.88M)
Operating Margin—————
Interest Income01.38M4.62M8.13M8.32M
Interest Expense00000
Other Income / Expenses(11.81M)(109K)5.16M8.12M8.03M
Income Before Tax(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Net Margin—————
EPS (Basic)(4.24)(1.72)(1.30)(1.53)(0.88)
EPS (Diluted)(4.24)(1.72)(1.30)(1.53)(0.88)
Weighted Avg Shares12.26M26.31M26.99M48.16M67.81M
Weighted Avg Shares (Diluted)12.26M26.31M26.99M48.16M67.81M

Climb Bio, Inc.

NASDAQ:CLYM

Intrinsic Alpha fair value

Locked

Current Price

$9.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.